{"id":"f6c9dc23-64a1-50f5-a49b-2dd5c7d2bc35","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-bigger-acyl-group-selective","predicate":"inhibits","statement":"Valeryl (pentanoyl) salicylate was the only compound of eight acyl salicylates to show isozyme selectivity and inhibited human cyclooxygenase-1 much more effectively than cyclooxygenase-2 in a time-dependent manner, inhibited ovine cyclooxygenase-1 but did not inhibit the S530A mutant of ovine cyclooxygenase-1 which is also refractory to acetylsalicylate, so valeryl salicylate acylates the active site serine.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"fbdad58c-1eff-5859-adeb-09c24ed9bfb1","mechanism_event_label":"Swap aspirin’s acetyl group for a bigger one and you get a drug that hits only the first enzyme.","subject":{"id":"1c054a0e-9c8c-51dd-9e03-3f33537c8da9","slug":"valeryl-salicylate","display_name":"Valeryl (pentanoyl) salicylate","entity_type_key":"chemical_species"},"object":{"id":"6284d26c-01e2-5e12-b192-ee391dd107e2","slug":"ptgs1","display_name":"Cyclooxygenase-1 (PTGS1)","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"fbdad58c-1eff-5859-adeb-09c24ed9bfb1","stable_key":"f8641d02-8413-5bd8-92e9-62ad49286e81:asa-bigger-acyl-group-selective-event","event_type":"biochemical_relationship","label":"Swap aspirin’s acetyl group for a bigger one and you get a drug that hits only the first enzyme.","description":"Valeryl (pentanoyl) salicylate was the only compound of eight acyl salicylates to show isozyme selectivity and inhibited human cyclooxygenase-1 much more effectively than cyclooxygenase-2 in a time-dependent manner, inhibited ovine cyclooxygenase-1 but did not inhibit the S530A mutant of ovine cyclooxygenase-1 which is also refractory to acetylsalicylate, so valeryl salicylate acylates the active site serine.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4fe60c95-70b9-5c25-9191-8e71f508fc7e","slug":"cox1-s530a","display_name":"Cyclooxygenase-1 with alanine substituted at position 530","entity_type_key":"protein_state"},"role":"refractory_mutant","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"7a465c55-930d-54cf-89b3-952b2c16f558","slug":"cox1-ser530","display_name":"Serine 530 of cyclooxygenase-1","entity_type_key":"protein_state"},"role":"acylated_residue","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c8a31ed4-f2ca-5d43-8352-e9935129a785","slug":"ptgs2","display_name":"Cyclooxygenase-2 (PTGS2)","entity_type_key":"protein"},"role":"spared_isoform","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"1c054a0e-9c8c-51dd-9e03-3f33537c8da9","slug":"valeryl-salicylate","display_name":"Valeryl (pentanoyl) salicylate","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"6284d26c-01e2-5e12-b192-ee391dd107e2","slug":"ptgs1","display_name":"Cyclooxygenase-1 (PTGS1)","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/aspirin-research/7872783.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b\", \"start_char\": 0, \"end_char\": 1756, \"text_sha256\": \"f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Eight acyl salicylates tested against human cyclooxygenase-1 and -2 expressed transiently in cos-1 cells, with the S530A mutant as a control","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Valeryl salicylate and related esters compared with acetylsalicylate","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Uses the acetylation chemistry as a design principle and confirms the serine requirement with a mutant. Recombinant enzyme and a murine fibroblast line, not human tissue.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.","comparator":null,"unit":null,"notes":"","entity":{"slug":"aspirin","display_name":"Aspirin / acetylsalicylic acid","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human and sheep enzyme","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Swap aspirin’s acetyl group for a bigger one and you get a drug that hits only the first enzyme.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[asa-p7872783] Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. (1995). https://pubmed.ncbi.nlm.nih.gov/7872783/ DOI: 10.1006/abbi.1995.1130","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Recombinant cyclooxygenase","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"197fccb7-a425-5012-b5b9-d7742df2ec87","evidence_kind":"source_excerpt","locator":"Lines 182-193","start_line":182,"end_line":193,"excerpt":"### asa-bigger-acyl-group-selective\nValeryl (pentanoyl) salicylate was the only compound of eight acyl salicylates to show isozyme selectivity and inhibited human cyclooxygenase-1 much more effectively than cyclooxygenase-2 in a time-dependent manner, inhibited ovine cyclooxygenase-1 but did not inhibit the S530A mutant of ovine cyclooxygenase-1 which is also refractory to acetylsalicylate, so valeryl salicylate acylates the active site serine.\nCondition category: normal\nnutrient_topic: Aspirin research collection; topical membership is not evidence of a direct clinical effect, and aspirin is recorded separately from salicylate, the metabolite it becomes.\nplain_language: Swap aspirin’s acetyl group for a bigger one and you get a drug that hits only the first enzyme.\norganism: Human and sheep enzyme\ntissue_or_cell_type: Recombinant cyclooxygenase\nexperimental_model: Eight acyl salicylates tested against human cyclooxygenase-1 and -2 expressed transiently in cos-1 cells, with the S530A mutant as a control\nlimitations: Uses the acetylation chemistry as a design principle and confirms the serine requirement with a mutant. Recombinant enzyme and a murine fibroblast line, not human tissue.\nexposure: Valeryl salicylate and related esters compared with acetylsalicylate\nevidence_span: {\"source_cache\": \"artifacts/aspirin-research/7872783.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b\", \"start_char\": 0, \"end_char\": 1756, \"text_sha256\": \"f7e8a07a2704cb600938505ec51355671355769c01868ed0966731382901425b\"}\n[asa-p7872783] Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. (1995). https://pubmed.ncbi.nlm.nih.gov/7872783/ DOI: 10.1006/abbi.1995.1130","model_system":"Eight acyl salicylates tested against human cyclooxygenase-1 and -2 expressed transiently in cos-1 cells, with the S530A mutant as a control","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [asa-p7872783] Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. (1995). https://pubmed.ncbi.nlm.nih.gov/7872783/ DOI: 10.1006/abbi.1995.1130","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"712cf519-cd27-5a8b-9e2f-961a98d7a27e","stable_key":"import-f8641d02-8413-5bd8-92e9-62ad49286e81","title":"Aspirin: the serine it acetylates, the enzyme that acetylation creates, the dose that separates platelet from vessel wall, and the metabolite that is a different drug (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"93dd4343051c131e40d4fc3c95a978cd65478c13dcdb3f2d42507c49b09cb647","revision_id":"694e8ee7-49ca-5e6c-b58b-8ba8f82c2ad8","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}